The Netherlands Cancer Institute (NKI) selects Labguru to further pioneering cancer research and treatment

NKI completes institute wide adoption of Labguru to increase efficiency and maximize productivity in the laboratory

12 March 2019, Cambridge, MA: BioData has announced The Netherlands Cancer Institute (NKI) has started an institute wide deployment of its flagship product Labguru. NKI has secured an institutional licence of Labguru’s Electronic Lab Notebook (ELN) for further collaboration across its team of researchers. Following a successful three-month pilot with a selected group of researchers, the NKI initiated instant deployment for the whole institute to start utilizing the full functionality and benefit from increased data quality, reduced time and costs, secure access anywhere in the world from any device, ease of reporting and full regulatory compliance.

The NKI, established in 1913, has over 600 scientists and scientific support personnel working to study cancer and related diseases. With Labguru, researchers at The NKI will be able to easily manage and document their experiments, manage inventory and be able to connect and process research data from different software applications within the institute via a cloud-based system.

Previously, the institute had a diverse environment for documenting experiments and research with a vast majority prepared on paper. By using Labguru across the institute, data will be kept and managed easily, allowing for a smooth collaboration between all scientists, something the institute relies on.

Henri van Luenen, Manager Research, from The Netherlands Cancer Institute (NKI) stated: “As the only comprehensive cancer centre in The Netherlands, it is important for us to maintain our role as an international center of scientific expertize, development and training. We already have centralized technology facilities that serve the whole institute, therefore, it makes sense to incorporate Labguru’s ELN into our institute. We chose Labguru mainly because it is a comprehensive system that incorporates ELN with inventory management, allowing us to create links between experiments and samples, along with a compelling user interface. In addition, Labguru offers various communication options that allow better cooperation within and between our different research groups.”

Labguru is creating a whole series of new functional enhancements to the ELNs as a result of this arrangement and the ELN will be used as an e-notebook management system. Steve Yemm, CEO at Labguru’s, BioData said: “The Netherlands Cancer Institute (NKI) has a prestigious reputation for being at the forefront of cancer research and treatment, making it very exciting that Labguru will support its innovations. Having the NKI recognize Labguru’s abilities, further enhances our vision of a bright future in which scientists can focus on efficiently delivering invaluable work, while their data and inventory management is taken care of.” 

To learn more about Labguru, visit www.labguru.com, or call us at +1-617-714-9952.

Ends


For press information, please contact: Amica Morris, The Scott Partnership, Tel: + 44 1477 539539 mail to biodata@scottpr.com.

About BioData

BioData delivers SaaS software solutions for institutions and companies in the life sciences. BioData´s flagship product Labguru is a secure, web-based Electronic Lab Notebook (ELN) which records and manages laboratory data and inventory, helping labs to run more efficiently. With Labguru, scientists can design experiments and workflows, capture structured and unstructured data, manage projects, and share their work. Customisable experiment templates, integration of protocols, SOPs, and other cutting-edge features help to increase data quality, streamline workflows and reduce costs. BioData is part of the Digital Science portfolio of companies all working together to help researchers make a difference. For more information, visit www.labguru.com.